Elizabeth Partridge1, Eduardo Lujan1, Serena Giuntini1, David M Vu1, Dan M Granoff2. 1. Center for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital, Oakland, CA 94609, USA. 2. Center for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital, Oakland, CA 94609, USA. Electronic address: dgranoff@chori.org.
Abstract
BACKGROUND: MenB-4C (Bexsero®) is a multicomponent serogroup B meningococcal vaccine. For vaccine licensure, efficacy was inferred from serum bactericidal antibody (SBA) against three antigen-specific indicator strains. The bactericidal role of antibody to the fourth vaccine antigen, Neisserial Heparin binding antigen (NHba), is incompletely understood. METHODS: We identified nine adults immunized with two or three doses of MenB-4C who had sufficient volumes of sera and >3-fold increases in SBA titer against a strain with high NHba expression, which was mismatched with the other three MenB-4C antigens that elicit SBA. Using 1month-post-immunization sera we measured the effect of depletion of anti-NHba and/or anti-Factor H binding protein (FHbp) antibodies on SBA. RESULTS: Against three strains matched with the vaccine only for NHba, depletion of anti-NHba decreased SBA titers by an average of 43-79% compared to mock-adsorbed sera (P<0.05). Despite expression of sub-family A FHbp (mismatched with the sub-family B vaccine antigen), depletion of anti-FHbp antibodies also decreased SBA by 45-64% (P<0.05). Depletion of both antibodies decreased SBA by 84-100%. Against a strain with sub-family B FHbp and expression of NHba with 100% identity to the vaccine antigen, depletion of anti-NHba decreased SBA by an average of 26%, compared to mock-adsorbed sera (P<0.0001), and depletion of anti-FHbp antibody decreased SBA by 92% (P<0.0001). CONCLUSIONS: Anti-NHba antibody can contribute to SBA elicited by MenB-4C, particularly in concert with anti-FHbp antibody. However, some high NHba-expressing strains are resistant, even with an exact match between the amino acid sequence of the vaccine and strain antigens.
BACKGROUND: MenB-4C (Bexsero®) is a multicomponent serogroup B meningococcal vaccine. For vaccine licensure, efficacy was inferred from serum bactericidal antibody (SBA) against three antigen-specific indicator strains. The bactericidal role of antibody to the fourth vaccine antigen, NeisserialHeparin binding antigen (NHba), is incompletely understood. METHODS: We identified nine adults immunized with two or three doses of MenB-4C who had sufficient volumes of sera and >3-fold increases in SBA titer against a strain with high NHba expression, which was mismatched with the other three MenB-4C antigens that elicit SBA. Using 1month-post-immunization sera we measured the effect of depletion of anti-NHba and/or anti-Factor H binding protein (FHbp) antibodies on SBA. RESULTS: Against three strains matched with the vaccine only for NHba, depletion of anti-NHba decreased SBA titers by an average of 43-79% compared to mock-adsorbed sera (P<0.05). Despite expression of sub-family A FHbp (mismatched with the sub-family B vaccine antigen), depletion of anti-FHbp antibodies also decreased SBA by 45-64% (P<0.05). Depletion of both antibodies decreased SBA by 84-100%. Against a strain with sub-family B FHbp and expression of NHba with 100% identity to the vaccine antigen, depletion of anti-NHba decreased SBA by an average of 26%, compared to mock-adsorbed sera (P<0.0001), and depletion of anti-FHbp antibody decreased SBA by 92% (P<0.0001). CONCLUSIONS: Anti-NHba antibody can contribute to SBA elicited by MenB-4C, particularly in concert with anti-FHbp antibody. However, some high NHba-expressing strains are resistant, even with an exact match between the amino acid sequence of the vaccine and strain antigens.
Authors: Guillermo Madico; Jo Anne Welsch; Lisa A Lewis; Anne McNaughton; David H Perlman; Catherine E Costello; Jutamas Ngampasutadol; Ulrich Vogel; Dan M Granoff; Sanjay Ram Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Matthew D Snape; Tom Dawson; Philipp Oster; Anita Evans; Tessa M John; Brigitte Ohene-Kena; Jamie Findlow; Ly-Mee Yu; Ray Borrow; Ellen Ypma; Daniela Toneatto; Andrew J Pollard Journal: Pediatr Infect Dis J Date: 2010-11 Impact factor: 2.129
Authors: Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff Journal: J Immunol Date: 2011-02-16 Impact factor: 5.422
Authors: Davide Serruto; Tiziana Spadafina; Laura Ciucchi; Lisa A Lewis; Sanjay Ram; Marta Tontini; Laura Santini; Alessia Biolchi; Kate L Seib; Marzia M Giuliani; John J Donnelly; Francesco Berti; Silvana Savino; Maria Scarselli; Paolo Costantino; J Simon Kroll; Clíona O'Dwyer; Jiazhou Qiu; Andrew G Plaut; Richard Moxon; Rino Rappuoli; Mariagrazia Pizza; Beatrice Aricò Journal: Proc Natl Acad Sci U S A Date: 2010-02-03 Impact factor: 11.205
Authors: Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick Journal: Infect Immun Date: 2004-04 Impact factor: 3.441
Authors: Irene Rivero-Calle; Peter Francis Raguindin; Jose Gómez-Rial; Carmen Rodriguez-Tenreiro; Federico Martinón-Torres Journal: Infect Drug Resist Date: 2019-10-09 Impact factor: 4.003
Authors: Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer Journal: Vaccine Date: 2020-08-30 Impact factor: 3.641